Statins are associated with reduced risk of gastric cancer: a meta-analysis. 2013

Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
Department of Anesthesiology, Fujian Provincial Hospital, Fujian Provincial Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, 350001, China.

BACKGROUND Statins are widely prescribed to reduce cholesterol levels in the prevention of atherosclerotic cardiovascular disease. However, the debate about the effect of statins on cancer risk remains unsettled. The aim of this study was to investigate the association of utilization of statins with the risk of gastric cancer by carrying out a meta-analysis. METHODS A literature search was performed on PubMed and EMBASE up to March 2013 to identify the cohort or case-control studies or randomized controlled trials (RCTs) that examined the relationship between statins use and the risk of gastric cancer. The bibliographies of the retrieved articles were also reviewed to identify additional studies. A random-effects model was used to calculate the summary relative risks (RRs) with 95 % confidence intervals (CIs). RESULTS Three post-hoc analyses of 26 RCTs involving 290 gastric cancers and eight observational studies totaling 7,321 gastric cancers were included. Statins use was shown to be significantly associated with a 27 % reduction in the risk of gastric cancer (RR = 0.73, 95 % CI = 0.58-0.93), with considerable heterogeneity among studies (I (2) = 88.9 %). Excluding one study in which all subjects are diabetic patients obtained an attenuated, but homogeneous result (RR = 0.85, 95 % CI = 0.80-0.91, I (2) = 0.0 %). These findings were consistent in the subgroup analysis. CONCLUSIONS A meta-analysis of existing evidence, primarily from observational studies, indicates that use of statins reduces the risk of gastric cancer.

UI MeSH Term Description Entries
D004363 Drug Utilization The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles. Utilization, Drug,Drug Utilizations,Utilizations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. HMG-CoA Reductase Inhibitor,HMG-CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Reductase Inhibitor,Statin,Statins, HMG-CoA,Inhibitors, HMG-CoA Reductase,Inhibitors, Hydroxymethylglutaryl-CoA,Inhibitors, Hydroxymethylglutaryl-Coenzyme A,Statins,HMG CoA Reductase Inhibitor,HMG CoA Reductase Inhibitors,HMG-CoA Statins,Hydroxymethylglutaryl CoA Reductase Inhibitor,Hydroxymethylglutaryl CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Inhibitors,Hydroxymethylglutaryl-Coenzyme A Inhibitors,Inhibitors, HMG CoA Reductase,Inhibitors, Hydroxymethylglutaryl CoA,Inhibitors, Hydroxymethylglutaryl Coenzyme A,Inhibitors, Hydroxymethylglutaryl-CoA Reductase,Reductase Inhibitor, Hydroxymethylglutaryl-CoA,Reductase Inhibitors, HMG-CoA,Reductase Inhibitors, Hydroxymethylglutaryl-CoA,Statins, HMG CoA
D064887 Observational Studies as Topic Works about clinical studies in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions (as in an interventional study). Natural Experiment as Topic,Natural Experiments as Topic,Naturalistic Observation Studies as Topic,Naturalistic Observation Study as Topic,Observational Study as Topic

Related Publications

Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
July 2013, Annals of oncology : official journal of the European Society for Medical Oncology,
Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
February 2013, Gastroenterology,
Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
December 2011, The American journal of gastroenterology,
Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
June 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
January 2022, International journal of clinical practice,
Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
March 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
January 2014, Cancer prevention research (Philadelphia, Pa.),
Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
April 2016, Medicine,
Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
January 2006, JAMA,
Xiao-Dan Wu, and Kai Zeng, and Fang-Qin Xue, and Jin-Hua Chen, and Yan-Qing Chen
December 2022, Journal of clinical medicine,
Copied contents to your clipboard!